Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
341 to 360 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cerebral Folate Transport Deficiency in 2 Cases with Intractable Myoclonic Epilepsy. | J Epilepsy Res | 2024 | 38978529 | PubTator, text mining | PubMed |
| New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review. | Front Pharmacol | 2024 | 38948462 | PubTator, text mining | PubMed |
| Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities. | Gynecol Oncol | 2024 | 38941962 | PubTator, text mining | PubMed |
| Expression of the Folate Receptor Proteins FOLR1 and FOLR2 in Correlation With Clinicopathological Variables of Gastric Cancer. | Cureus | 2024 | 38915965 | PubTator, text mining | PubMed |
| Lessons learned in application driven imaging agent design for image-guided surgery. | Eur J Nucl Med Mol Imaging | 2024 | 38900308 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial. | Int J Gynecol Cancer | 2024 | 38858103 | PubTator, text mining | PubMed |
| Dolutegravir induces FOLR1 expression during brain organoid development. | Front Mol Neurosci | 2024 | 38828282 | PubTator, text mining | PubMed |
| Evaluation of transport mechanisms of methotrexate in human choriocarcinoma cell lines by LC-MS/MS. | J Pharm Biomed Anal | 2024 | 38823222 | PubTator, text mining | PubMed |
| Targeted Photodynamic Therapy using a Vectorized Photosensitizer coupled to Folic Acid Analog induces Ovarian Tumor Cell Death and inhibits IL-6-mediated Inflammation. | J Control Release | 2024 | 38789088 | PubTator, text mining | PubMed |
| Challenges in Pharmacokinetic Modelling of [18F]fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer Patients. | Mol Imaging Biol | 2024 | 38775919 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer. | Medicine (Baltimore) | 2024 | 38758856 | PubTator, text mining | PubMed |
| Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer. | Cancers (Basel) | 2024 | 38730739 | PubTator, text mining | PubMed |
| Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer. | Front Immunol | 2024 | 38694498 | PubTator, text mining | PubMed |
| Customizable Porphyrin Platform Enables Folate Receptor PET Imaging Using Copper-64. | Mol Pharm | 2024 | 38623055 | PubTator, text mining | PubMed |
| Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. | J Gynecol Oncol | 2024 | 38576343 | PubTator, text mining | PubMed |
| Altered placental immune cell composition and gene expression with isolated fetal spina bifida. | Am J Reprod Immunol | 2024 | 38528656 | PubTator, text mining | PubMed |
| Role of folate receptor α in the partial rejuvenation of dentate gyrus cells: Improvement of cognitive function in 21-month-old aged mice. | Sci Rep | 2024 | 38519576 | PubTator, text mining | PubMed |
| Click chemistry in the development of PROTACs. | RSC Chem Biol | 2024 | 38456041 | PubTator, text mining | PubMed |
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. | Gynecol Oncol | 2024 | 38447347 | PubTator, text mining | PubMed |
| Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises. | Int J Mol Sci | 2024 | 38396800 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=18